AgingBefore/AfterNCT07118943
Efficacy of Four Topical Products to Improve Skin Longevity
A study testing Face care product in people with Aging and Wrinkle, run by Amazentis SA at 1 site in Canada.
Trial summary
The objective of this study is to determine the efficacy of four topical products to improve facial skin longevity over an eight-week use period utilizing analysis of images and self-perception questionnaires. Read more about this study
- Who is it for?
- Ages 40 to 65 yearsHealthy volunteers can take part
- What is being tested?
- Face care product
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 132 participants
- Where
- 1 siteCanada
- Study dates
- 12 Aug 2025to 9 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy female and male volunteers aged 40 to 65 years with no signs of skin disorders.
- Subject is willing and able to read, understand, and provide written Informed Consent and signed photo release.
- Subject has a score of 3.0 to 6.0 for clinically graded visible facial wrinkles using the Fitzpatrick Classification of Facial Wrinkling scale at Baseline, to determine eligibility for the creams or serum test articles or 3.0 to 6.0 for clinically graded visible wrinkles in the eye area using a wrinkling scale for the eye cream test article.
- Subject is willing to refrain from applying/using moisturizer, creams, serums or treatment/anti-aging products to their face during the three days prior to Visit 1 (Baseline). Subject's other regular skin products such as cleanser, sunscreen and cosmetics are acceptable.
- Subject is willing to come to the test facility with a clean face free of makeup and sunscreen prior to all visits.
- Subject is a regular sunscreen user (uses at least 2 times a week).
Show all 12Show fewer
- Subject is willing to avoid direct sun exposure and/or to apply sunscreen to their face in the event of sun exposure.
- Subject agrees to remove jewelry and false eye lashes before the visits.
- Subject agrees not to introduce any new personal care products or cosmetics to the face while participating on the study.
- Subject is willing to avoid use of tanning beds and any use of sunless tanners on the face throughout the study.
- Subject is willing to follow study instructions and available to attend all the study visits.
- Male only: Male subjects are willing to come to all visits with a clean-shaven face. Goatee and/or mustache are acceptable.
Who cannot join
- Female only: Pregnant or lactating or planning a pregnancy during the course of the study. (self-reported).
- Piercing or tattoos including permanent or semi-permanent make-up on the face which may interfere with study assessments.
- Any conditions on the face that would interfere with evaluations (i.e. full beard, scars, open cuts, sunburn, severe hyperpigmentation, facial hair/peach fuzz, etc.) or active acne or acne marks.
- Any skin conditions such as rosacea, eczema, psoriasis, seborrheic dermatitis, vitiligo, etc., or is under the treatment of a doctor for any skin condition on the face.
- Use of a self-tanner/stain on the face within two weeks of the study start.
- Allergies or sensitivities to facial moisturizer products, similar materials or their ingredients or cosmetics.
Show all 15Show fewer
- Insulin-dependent diabetes.
- Hematological or immune deficiency disease such as HIV positive, AIDS, Systemic Lupus Erythematosus.
- Recent use within the last 14 days of a chemical peel or is currently using an in-home or professional chemical peel on their facial skin.
- Subject has had a cosmetic medical procedure in the test area such as injectable anti-wrinkle products (e.g. Botox), facial cosmetic surgery, etc. in the last year.
- Current use of OTC (over the counter) pain medication ingested in quantities exceeding label use.
- Use of topical treatments such as OTC (over-the-counter) acne medication, hydroquinone, or hydrocortisone on the face in the last month.
- Currently participating in another clinical study or trial involving the face.
- Subject has been diagnosed with any type of cancer especially skin cancer within the past 12 months or treated for cancer in the last 5 years.
- Subject has any medical condition which, in the opinion of the Investigator, would compromise the safety of the subject or confound study results.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Study to Determine the Efficacy of Four Test Articles to Improve Skin Longevity Over Eight Weeks Use Period
The objective of this study is to determine the efficacy of four topical products to improve facial skin longevity over an eight-week use period utilizing analysis of images and self-perception questionnaires.
- Being tested
- Face care product
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Face care productOther
The topical product will be applied twice daily (morning and night).
Face care productOther
The topical product will be applied twice daily (morning and night).
Face care productOther
The topical product will be applied twice daily (morning and night).
Face care productOther
The topical product will be applied twice daily (morning and night).
| Study group | Role | What they receive |
|---|---|---|
| Face care product (eye cream) | Experimental | The topical product (eye cream) containing Mitopure will be used for eight weeks. Receives: Other: Face care product |
| Face care product (cream A) | Experimental | The topical product (moisturizing formula A) containing Mitopure will be used for eight weeks. Receives: Other: Face care product |
| Face care product (cream B) | Experimental | The topical product (moisturizing formula B) containing Mitopure will be used for eight weeks. Receives: Other: Face care product |
| Face care product (serum) | Experimental | The topical product (serum) containing Mitopure will be used for eight weeks. Receives: Other: Face care product |
What is being measured
The primary outcome is the main question the study is designed to answer.
Product Acceptance
Product Acceptance will be evaluated via questionnaire (measurement tool) responses after eight weeks of product use (time frame) and quantified as a single percentage score (unit of measure=%; minimum value=0%; maximum value=100%) so higher scores (closer to 100%) represent better Product Acceptance.
Participants will respond to 12 closed questions by ticking one of four predefined options: -2=Fully disagree; -1=Rather disagree; 1=Rather agree; 2=Fully agree. For each question, every participant's response will be categorized as "disagree" (scores -2, -1) or "agree" (scores 1, 2). The percentage of participants that respond "agree" will be calculated ([number of "agree" responses/total number of responses]*100%), yielding one overall "agreement" value (unit of measure = %) for each of the 12 questions. Product Acceptance will be calculated by averaging the 12 overall "agreement" values. Clear product acceptance will be determined if the Product Acceptance score is at least 70%.
Measured: 8 weeks
Secondary outcomes (4)
Skin wrinkles
Three-dimensional facial images will be taken with Phaseshift Rapid In vivo Measurement Of the Skin (PRIMOS) at baseline, week 4, and week 8 and will be analyzed for skin wrinkle size (unit of measure is millimeters).
Measured: 8 weeks
Haut AI Facial Analysis
High resolution digital facial VISIA images will be taken of right side, left side and front of the face with VISIA® CRP-GEN 5 at baseline, week 4, and week 8. The front face image will be analyzed by Haut AI for overall facial age health score (scale of 0 to 100, in which higher score represents better outcome).
Measured: 8 weeks
Self-perceived product traits
Subjective evaluation of 12 product traits assessed via questionnaire after 4 and 8 weeks. Product traits will be assessed by the subjects with a list of closed questions with the following predefined identical options to tick: -2 = Fully disagree; -1 = Rather disagree; 1 = Rather agree; 2 = Fully agree.
Self-perceived product trait will be calculated for each of the 12 product traits independently. For each trait, total percentages resulting in at least 80% agreement will represent a clear level of agreement and opinion of the panel. Frequencies between 70% to 80% will represent a high level of agreement. Less than 70% agreement will represent constrained and undecided agreement.
Measured: 8 weeks
Adverse Events
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2025
- Study start12 Aug 2025
- Primary completion9 Oct 2025
- Study completion9 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 132 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amazentis SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Princeton Consumer Research
- Responsible party
- Sponsor
- Investigators
- Nalini Kaul, PhD, Principal investigator, Princeton Consumer Research Corp.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07118943
- Sponsor's protocol ID
- ASACLI1W
- Acronym
- Before/After
- Status last verified
- Nov 2025
- First submitted
- 4 Aug 2025
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Determine the Efficacy of Four Test Articles to Improve Skin Longevity Over Eight Weeks Use Period
- ClinicalTrials.gov ID
- NCT07118943
- Acronym / sponsor ID
- Before/After / ASACLI1W
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 132 participants (actual)
- Lead sponsor
- Amazentis SAIndustry (pharma, biotech, devices)
- Collaborators
- Princeton Consumer Research
- Study start
- 12 Aug 2025 (actual)
- Primary completion
- 9 Oct 2025 (actual)
- Study completion
- 9 Oct 2025 (actual)
- First posted
- 12 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to determine the efficacy of four topical products to improve facial skin longevity over an eight-week use period utilizing analysis of images and self-perception questionnaires.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Face care product (eye cream) | Experimental | Other: Face care productThe topical product (eye cream) containing Mitopure will be used for eight weeks. |
| Face care product (cream A) | Experimental | Other: Face care productThe topical product (moisturizing formula A) containing Mitopure will be used for eight weeks. |
| Face care product (cream B) | Experimental | Other: Face care productThe topical product (moisturizing formula B) containing Mitopure will be used for eight weeks. |
| Face care product (serum) | Experimental | Other: Face care productThe topical product (serum) containing Mitopure will be used for eight weeks. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Healthy female and male volunteers aged 40 to 65 years with no signs of skin disorders.
- Subject is willing and able to read, understand, and provide written Informed Consent and signed photo release.
- Subject has a score of 3.0 to 6.0 for clinically graded visible facial wrinkles using the Fitzpatrick Classification of Facial Wrinkling scale at Baseline, to determine eligibility for the creams or serum test articles or 3.0 to 6.0 for clinically graded visible wrinkles in the eye area using a wrinkling scale for the eye cream test article.
- Subject is willing to refrain from applying/using moisturizer, creams, serums or treatment/anti-aging products to their face during the three days prior to Visit 1 (Baseline). Subject's other regular skin products such as cleanser, sunscreen and cosmetics are acceptable.
- Subject is willing to come to the test facility with a clean face free of makeup and sunscreen prior to all visits.
Key exclusion criteria (15 listed)
- Female only: Pregnant or lactating or planning a pregnancy during the course of the study. (self-reported).
- Piercing or tattoos including permanent or semi-permanent make-up on the face which may interfere with study assessments.
- Any conditions on the face that would interfere with evaluations (i.e. full beard, scars, open cuts, sunburn, severe hyperpigmentation, facial hair/peach fuzz, etc.) or active acne or acne marks.
- Any skin conditions such as rosacea, eczema, psoriasis, seborrheic dermatitis, vitiligo, etc., or is under the treatment of a doctor for any skin condition on the face.
- Use of a self-tanner/stain on the face within two weeks of the study start.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Face care productThe topical product will be applied twice daily (morning and night). | Other | Face care product (cream A) |
| Face care productThe topical product will be applied twice daily (morning and night). | Other | Face care product (cream B) |
| Face care productThe topical product will be applied twice daily (morning and night). | Other | Face care product (eye cream) |
| Face care productThe topical product will be applied twice daily (morning and night). | Other | Face care product (serum) |
Primary outcome
Product Acceptance
Time frame: 8 weeks
Product Acceptance will be evaluated via questionnaire (measurement tool) responses after eight weeks of product use (time frame) and quantified as a single percentage score (unit of measure=%; minimum value=0%; maximum value=100%) so higher scores (closer to 100%) represent better Product Acceptance. Participants will respond to 12 closed questions by ticking one of four predefined options: -2=Fully disagree; -1=Rather disagree; 1=Rather agree; 2=Fully agree. For each question, every participant's response will be categorized as "disagree" (scores -2, -1) or "agree" (scores 1, 2). The percentage of participants that respond "agree" will be calculated ([number of "agree" responses/total number of responses]*100%), yielding one overall "agreement" value (unit of measure = %) for each of the 12 questions. Product Acceptance will be calculated by averaging the 12 overall "agreement" values. Clear product acceptance will be determined if the Product Acceptance score is at least 70%.
4 secondary outcomes
Skin wrinkles
Time frame: 8 weeks
Haut AI Facial Analysis
Time frame: 8 weeks
Self-perceived product traits
Time frame: 8 weeks
Adverse Events
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nalini Kaul, PhD principal investigator
Princeton Consumer Research Corp.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Face care product in people with Aging and Wrinkle, run by Amazentis SA at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Product Acceptance (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.